Bildkälla: Stockfoto

Mendus: Adjusting our estimates for ilixadencel - Redeye

Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as part of the REGOMUNE trial.

Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as part of the REGOMUNE trial.
Börsvärldens nyhetsbrev
ANNONSER